Supplemental Table 1. Details of genetic testing performed

Of the genetic testing conducted, a commercial panel testing for glycogen storage diseases (sequencing of *AGL, G6PC, GAA, GBE1, GYS2, PFKM, PHKA1, PHKA2, PHKB, PHKG2, PYGL, PYGM, SLC2A2*, and *SLC37A4*) was obtained most frequently, in 14 patients. A ketotic hypoglycemia panel (sequencing and deletion/duplication analysis of *ACAT1, AGL, G6PC, GYS2, PHKA2, PHKB, PHKG2, PYGL, SLC16A1*, and *SLC37A4*) was obtained in 10 patients, hyperinsulinism panel (including sequencing of *ABCC8, KCNJ11, GCK, GLUD1* in all cases, with the addition of sequencing and deletion/duplication analysis of *ABCC8, KCNJ11, GLUD1, HADH, HNF1A, HNF4A, INSR, SLC16A1, UCP2* depending on the panel utilized) was obtained in six patients, fatty acid oxidation defect panel (sequencing and deletion/duplication analysis of *ACADVL*) was obtained in five patients, isolated *SLC16A1* mutation analysis was performed in three patients, and one patient had a commercial metabolic hypoglycemia panel (sequencing of *ACAT1, AGL, ALDOB, FBP1, G6PC, GALT, GYS2, HMGCL, MLYCD, OXCT1, PC, PCK1, PCK2, PGM1, PHKA2, PHKB, PHKG2, PYGL, SLC16A1, SLC2A2*, and *SLC37A4*) obtained. One child had targeted testing for Russel Silver syndrome based upon clinical examination findings. Chromosomal microarray was obtained in one patient and four patients had whole exome sequencing.